NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Instruments & Supplies · USD

Stevanato Group S.p.A. (STVN) Stock Analysis

Stevanato Group S.p.A. (STVN) is a Medical Instruments & Supplies stock listed on NYSE and quoted in US Dollar.

STVN

$20.51

−$0.03 (−0.15%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare STVN with… →

STVN Key Statistics

As of Sep 4, 2026
Trading
Open
$20.26
Previous Close
$20.54
Day's Range
19.74–20.60
52-Week Range
12.89–28.00
Volume
212.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.75
Valuation
Market Cap
$5.60B
P/E Ratio
35.98
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
24.40
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.48
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.57
EPS (ttm)Profit attributable to each share over the last twelve months.
0.57
Financials (FY)
Revenue (FY)
$1.19B+7.45%
Net Income (FY)
$139.84M+18.73%
Profit marginThe share of revenue left as profit after all costs and taxes.
10.99%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
49.83M
1-Year Return
−10.66%
Dividend and dates
Dividend
$0.06+0.30%
Ex-Dividend Date
June 11, 2026
Earnings Date
November 5, 2026
Avg Volume
397.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

STVN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+2.31%
2025−7.41%
2024−19.92%
2023+52.18%
2022−19.66%
2021 (partial year)+14.13%

As of September 4, 2026.

STVN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.19B$139.84M11.8%
2024$1.10B$117.78M10.7%
2023$1.09B$145.63M13.4%
2022$983.68M$142.85M14.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.19B$343.88M$198.80M$139.84M11.8%
2024$1.10B$302.32M$161.14M$117.78M10.7%
2023$1.09B$339.89M$200.72M$145.63M13.4%
2022$983.68M$319.80M$192.43M$142.85M14.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

STVN Dividend History

$0.06+6.9% vs 2024

Dividends per share, 2025 · 1 payments

YearDividends per sharePaymentsChange
2026*$0.061—
2025$0.061+6.9%
2024$0.061+0.0%
2023$0.061+7.4%
YearDividends per sharePaymentsChange
2026 (partial year)$0.061—
2025$0.061+6.9%
2024$0.061+0.0%
2023$0.061+7.4%
2022$0.051—

Most recent payment: $0.06 per share, ex-dividend June 11, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

STVN Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricSTVNMedical Instruments & Supplies medianvs median
P/E35.9835.611% above
P/S ratio4.573.1744% above
Profit margin10.99%0.85%10.1 pts above

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Stevanato Group S.p.A. (STVN) is capitalised at $5.60B on the latest close. The company sits in the Healthcare sector, in the Medical Instruments & Supplies industry. Headcount on file is 6,010.

Over the past 52 weeks the price has ranged from $12.89 to $28.00. The most recent close on file for STVN is $20.51, dated September 4, 2026. That is −$0.03 (−0.15%) against the previous close. The latest close sits 59.12% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.19B. Against the prior fiscal year total of $1.10B, that is a change of +7.45%. Net income for the same year was $139.84M. That is +18.73% against the prior fiscal year. The reported profit margin is 10.99%. That is 10.1 percentage points above the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to 0.57.

Across the 4 fiscal years on file, revenue moves from $983.68M in 2022 to $1.19B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 35.98. That is 1.02% above the Medical Instruments & Supplies median of 35.61. On forward earnings the ratio is 24.4. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.48. The price-to-sales ratio is 4.57. On price-to-sales that is 44.1% above the Medical Instruments & Supplies median of 3.17. 55 Medical Instruments & Supplies companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.75. Daily returns over the trailing 5 years annualize to a volatility of 49.72%. Over the trailing twelve months the price has returned −10.66%. Across 5 years the annualized return works out at −5.36%.

Growth & Income

Shareholders receive a dividend, yielding 0.3% on the latest price. That is 0.7 percentage points below the Medical Instruments & Supplies median yield of 0.97%. The indicated annual rate is $0.06 a share. The ex-dividend date on file is June 11, 2026. Dividends are recorded for 5 calendar years; 2026 shows 1 payments totalling $0.06 a share. The year before, 2025, totalled $0.06 a share.

The strongest complete calendar year on file is 2023 at +52.18%; the weakest is 2024 at −19.92%. Of the 4 complete calendar years on file, 1 finished higher. So far in 2026 the price is +2.31%.

Peer Comparison

Stevanato Group S.p.A. (STVN) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Stevanato Group S.p.A. STVN $5.60B 36.0
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Stevanato Group S.p.A. trades at a P/E of 36.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Stevanato Group S.p.A.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Visit website →